Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

A Highly Efficient Recombineering-Based Method for Generating Conditional Knockout MutationsPreprint

Liu, P., Jenkins, N. A., & Copeland, N. G. (2003) · Genome Research · doi:10.1101/gr.749203 · Cited by 1,013

‘Knobs-into-holes’ engineering of antibody C H 3 domains for heavy chain heterodimerization

Ridgway, J. B., Presta, L. G., & Carter, P. M. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.7.617 · Cited by 816

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794

Targeting the β secretase BACE1 for Alzheimer's disease therapy

Yan, R., & Vassar, R. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 645

Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622

Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation

Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549

Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants

Bien‐Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., Luk, W., Lu, Y., Dennis, M. S., Weimer, R. M., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131660 · Cited by 356

Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier

Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., Solanoy, H. O., Tong, R. K., Hoyte, K., Luk, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005338 · Cited by 278

A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo

Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274

Developing Therapeutic Antibodies for Neurodegenerative Disease

Yu, Y. J., & Watts, R. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0187-4 · Cited by 231

Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders

Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076

Blood-Brain Barrier: From Physiology to Disease and Back

Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312

Bispecific antibodies: a mechanistic review of the pipeline

Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303

Strategies for delivering therapeutics across the blood–brain barrier

Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138

In vitro models of the blood–brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use

Helms, H. C., Abbott, N. J., Burek, M., Cecchelli, R., Couraud, P.-O., Deli, M. A., Förster, C., Galla, H. J., Romero, I. A., Shusta, E. V., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16630991 · Cited by 843

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 780

Antibody Structure and Function: The Basis for Engineering Therapeutics

Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 711

Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies

Park, T., Mustafaoğlu, N., Herland, A., Hasselkus, R., Mannix, R. J., Fitzgerald, E. A., Prantil‐Baun, R., Watters, A. L., Henry, O., Benz, M. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10588-0 · Cited by 621

The vascular basement membrane in the healthy and pathological brain

Thomsen, M. S., Routhe, L. G., & Moos, T. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17722436 · Cited by 512

Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery

Oller‐Salvia, B., Sánchez‐Navarro, M., Giralt, E., & Teixidò, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 463

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Vassar, R. J. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 421

Ferritin Nanocarrier Traverses the Blood Brain Barrier and Kills Glioma

Fan, K., Jia, X., Zhou, M., Wang, K., Conde, J., He, J., Tian, J., & Yan, X. (2018) · ACS Nano · doi:10.1021/acsnano.7b06969 · Cited by 401

Targeting the transferrin receptor for brain drug delivery

Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 379

Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys

Kariolis, M. S., Wells, R. C., Getz, J. A., Kwan, W., Mahon, C. S., Tong, R. K., Kim, D. J., Srivastava, A., Bédard, C., Henne, K. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1359 · Cited by 362

Targeting cellular pathways in glioblastoma multiforme

Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 351

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice

Lo, M., Kim, H. S., Tong, R. K., Bainbridge, T. W., Vernes, J.-M., Zhang, Y., Lin, Y. L., Chung, S., Dennis, M. S., Zuchero, Y. J. Y., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767749 · Cited by 317

The Translational Significance of the Neurovascular Unit

McConnell, H. L., Kersch, C. N., Woltjer, R. L., & Neuwelt, E. A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.760215 · Cited by 314

Bispecific Antibodies: From Research to Clinical Application

Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 321

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299

Bispecific antibodies: design, therapy, perspectives

Sedykh, S. E., Prinz, V. Y., Buneva, V. N., & Nevinsky, G. A. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 297

Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies

Zuchero, Y. J. Y., Chen, X., Bien‐Ly, N., Bumbaca, D., Tong, R. K., Gao, X., Zhang, S., Hoyte, K., Luk, W., Huntley, M. A., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.11.024 · Cited by 286

Tau-based therapies in neurodegeneration: opportunities and challenges

Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272

Current progress in innovative engineered antibodies

Strohl, W. R. (2017) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 296

Exploiting Nanobodies’ Singular Traits

Ingram, J. R., Schmidt, F. I., & Ploegh, H. L. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053327 · Cited by 257

Smart drug delivery systems for precise cancer therapy

Wang, X., Li, C., Wang, Y., Chen, H., Zhang, X., Luo, C., Zhou, W., Li, L., Teng, L., Yu, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.013 · Cited by 256

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease

Sehlin, D., Fang, X. T., Cato, L., Antoni, G., Lannfelt, L., & Syvänen, S. (2016) · Nature Communications · doi:10.1038/ncomms10759 · Cited by 226

Brain penetrating peptides and peptide–drug conjugates to overcome the blood–brain barrier and target CNS diseases

Zhou, X., Smith, Q. R., & Liu, X. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1695 · Cited by 229

A Historical Review of Brain Drug Delivery

Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219

Peripheral immune system in aging and Alzheimer’s disease

Cao, W., & Zheng, H. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0284-2 · Cited by 214

Intracellular transport and regulation of transcytosis across the blood–brain barrier

Villaseñor, R., Lampe, J., Schwaninger, M., & Collin, L. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2982-x · Cited by 221

Brain delivery and activity of a lysosomal enzyme using a blood–brain barrier transport vehicle in mice

Ullman, J. C., Arguello, A., Getz, J. A., Bhalla, A., Mahon, C. S., Wang, J., Giese, T., Bedard, C., Kim, D. J., Blumenfeld, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1163 · Cited by 205

Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human

Zhang, W., Liu, Q. Y., Haqqani, A. S., Leclerc, S., Liu, Z., Fauteux, F., Baumann, E., Delaney, C. E., Ly, D., Star, A. T., et al. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00209-0 · Cited by 208

Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier

Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202

An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery

Huang, Q., Chan, K. Y., Wu, J. H., Botticello-Romero, N. R., Zheng, Q., Lou, S., Keyes, C., Svanbergsson, A., Johnston, J., Mills, A., et al. (2024) · Science · doi:10.1126/science.adm8386 · Cited by 201

A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II

Sonoda, H., Morimoto, H., Yoden, E., Koshimura, Y., Kinoshita, M., Golovina, G., Takagi, H., Yamamoto, R., Minami, K., Mizoguchi, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.032 · Cited by 200

Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery

Pardridge, W. M. (2020) · Pharmaceuticals · doi:10.3390/ph13110394 · Cited by 198

Minimally Invasive and Regenerative Therapeutics

Ashammakhi, N. A., Ahadian, S., Darabi, M. A., Tahchi, M. R. E., Lee, J., Suthiwanich, K., Sheikhi, A., Dokmeci, M. R., Öklü, R., & Khademhosseini, A. (2018) · Advanced Materials · doi:10.1002/adma.201804041 · Cited by 194

A D ‐Peptide Ligand of Nicotine Acetylcholine Receptors for Brain‐Targeted Drug Delivery

Wei, X., Zhan, C., Shen, Q., Fu, W., Xie, C., Gao, J., Peng, C., Zheng, P., & Lu, W. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201411226 · Cited by 181

Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans

Grimm, H. P., Schumacher, V. L., Schäfer, M. K.-H., Imhof-Jung, S., Freskgård, P., Brady, K., Hofmann, C., Rüger, P., Schlothauer, T., Göpfert, U., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2261509 · Cited by 180

Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease

Williams, T., Borchelt, D., & Chakrabarty, P. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0358-9 · Cited by 172

Leveraging Physiology for Precision Drug Delivery

Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169

Bispecific antibody drug conjugates: Making 1+1>2

Gu, Y., Wang, Z., & Wang, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.009 · Cited by 171

Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles

Johnsen, K. B., Bak, M., Kempen, P. J., Melander, F., Burkhart, A., Thomsen, M. S., Nielsen, M. S., Moos, T., & Andresen, T. L. (2018) · Theranostics · doi:10.7150/thno.25228 · Cited by 161

The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics

Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155

Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria

Haqqani, A. S., Bélanger, K., & Stanimirovic, D. B. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1360302 · Cited by 153

Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease

Rotman, M., Welling, M. M., Bunschoten, A., de Backer, M. E., Rip, J., Nabuurs, R. J. A., Gaillard, P. J., van Buchem, M. A., van der Maarel, S. M., & van der Weerd, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.012 · Cited by 151

Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial

Okuyama, T., Eto, Y., Sakai, N., Minami, K., Yamamoto, T., Sonoda, H., Yamaoka, M., Tachibana, K., Hirato, T., & Sato, Y. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.005 · Cited by 153

Strategies for non-viral vectors targeting organs beyond the liver

Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 160

Brain-on-a-chip: Recent advances in design and techniques for microfluidic models of the brain in health and disease

Amirifar, L., Shamloo, A., Nasiri, R., de Barros, N. R., Wang, Z. Z., Unluturk, B. D., Libanori, A., Ievglevskyi, O., Diltemiz, S. E., Sances, S., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121531 · Cited by 151

Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology

Pardridge, W. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0248-z · Cited by 152

Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy

Han, L., Liu, C., Qi, H., Zhou, J., Wen, J., Wu, D., Xu, D., Qin, M., Ren, J., Wang, Q., et al. (2019) · Advanced Materials · doi:10.1002/adma.201805697 · Cited by 148

A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer’s disease

Zhao, P., Xu, Y., Jiang, L., Fan, X., Li, L., Li, X., Arase, H., Zhao, Y., Cao, W., Zheng, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0095 · Cited by 141

Adenosine receptor signaling: a key to opening the blood–brain door

Bynoe, M. S., Viret, C., Yan, A., & Kim, D.-G. (2015) · Fluids and Barriers of the CNS · doi:10.1186/s12987-015-0017-7 · Cited by 143

Revisiting nanoparticle technology for blood–brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes

Johnsen, K. B., & Moos, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.032 · Cited by 134

The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease

Evans, J. C., Malhotra, M., Cryan, J. F., & O’Driscoll, C. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13576 · Cited by 127

Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents

Clark, I. A., & Vissel, B. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0708-2 · Cited by 123

Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis

Tashima, T. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00854 · Cited by 120

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment

Pearson, J. R. D., Cuzzubbo, S., McArthur, S., Durrant, L. G., Adhikaree, J., Tinsley, C. J., Pockley, A. G., & McArdle, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582106 · Cited by 118

Blood-brain barrier dysfunction and Alzheimer’s disease: associations, pathogenic mechanisms, and therapeutic potential

Chen, Y., He, Y., Han, J., Wei, W., & Chen, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1258640 · Cited by 116

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease

Ayalon, G., Lee, S.-H., Adolfsson, O., Foo‐Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H. S., Bravo, J., Brendza, R. P., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 112

An MMP-9 exclusive neutralizing antibody attenuates blood-brain barrier breakdown in mice with stroke and reduces stroke patient-derived MMP-9 activity

Ji, Y., Gao, Q., Ma, Y., Wang, F., Tan, X., Song, D., Hoo, R. L. C., Wang, Z., Ge, X., Han, H., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106720 · Cited by 114

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

Liu, H., Saxena, A., Sidhu, S. S., & Wu, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00038 · Cited by 114

Brain Shuttle Antibody for Alzheimer’s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode

Weber, F. C., Bohrmann, B., Niewoehner, J., Fischer, J. A. A., Rueger, P., Tiefenthaler, G., Moelleken, J., Bujotzek, A., Brady, K., Singer, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.019 · Cited by 107

Endothelial cells are critical regulators of iron transport in a model of the human blood–brain barrier

Chiou, B., Neal, E. H., Bowman, A. B., Lippmann, E. S., Simpson, I. A., & Connor, J. R. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18783372 · Cited by 108

Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier

Stanimirovic, D. B., Sandhu, J. K., & Costain, W. J. (2018) · BioDrugs · doi:10.1007/s40259-018-0309-y · Cited by 109

Advances and considerations in AD tau-targeted immunotherapy

Bittar, A., Bhatt, N. N., & Kayed, R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104707 · Cited by 106

Blood‐brain barrier transport using a high affinity, brain‐selective VNAR antibody targeting transferrin receptor 1

Stocki, P., Szary, J., Rasmussen, C. L. M., Demydchuk, M., Northall, L., Logan, D. B., Gauhar, A., Thei, L., Moos, T., Walsh, F. S., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202001787r · Cited by 108

Heparan sulfate proteoglycan‐mediated dynamin‐dependent transport of neural stem cell exosomes in an in vitro blood–brain barrier model

Joshi, B. S., & Zuhorn, I. S. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14974 · Cited by 102

Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier

Strazielle, N., & Ghersi‐Egea, J. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160726112115 · Cited by 104

CD98hc is a target for brain delivery of biotherapeutics

Chew, K. S., Wells, R. C., Moshkforoush, A., Chan, D., Lechtenberg, K. J., Tran, H. L., Chow, J., Kim, D. J., Robles‐Colmenares, Y., Srivastava, D. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40681-4 · Cited by 104

The blood–brain barrier: a help and a hindrance

Rust, R., Yin, H. R., Buil, B. A., Sagare, A. P., & Kisler, K. (2025) · Brain · doi:10.1093/brain/awaf068 · Cited by 109

Engineered antibodies: new possibilities for brain PET?

Sehlin, D., & Syvänen, S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04426-0 · Cited by 96

Targeted Drug Delivery to the Brain Using Magnetic Nanoparticles

Thomsen, L. B., Thomsen, M. S., & Moos, T. (2015) · Therapeutic Delivery · doi:10.4155/tde.15.56 · Cited by 100

Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins

Ha, J.-H., Kim, J.-E., & Kim, Y. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00394 · Cited by 92

Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier

Haqqani, A. S., Delaney, C. E., Brunette, E., Baumann, E., Farrington, G. K., Sisk, W. P., Eldredge, J. K., Ding, W., Tremblay, T., & Stanimirovic, D. B. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17740031 · Cited by 98

A translational platform PBPK model for antibody disposition in the brain

Chang, H.-Y., Wu, S., Meno‐Tetang, G. M. L., & Shah, D. K. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09641-8 · Cited by 87

Iron metabolism: a double-edged sword in the resistance of glioblastoma to therapies

Legendre, C., & Garcion, E. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.03.008 · Cited by 78

Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage

DeGregorio‐Rocasolano, N., Martı́, O., Ponce, J., Castelló‐Ruiz, M., Millán, M., Guirao, V., García‐Yébenes, I., Salom, J. B., Ramos‐Cabrer, P., Alborch, E., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.11.026 · Cited by 80

Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR

Pothin, E., Lesuisse, D., & Lafaye, P. J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100937 · Cited by 83

Identification and in vivo characterization of a brain-penetrating nanobody

Wouters, Y., Jaspers, T., Strooper, B. D., & Dewilde, M. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00226-z · Cited by 82

Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models

Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 80

Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size

Faresjö, R., Bonvicini, G., Fang, X. T., Aguilar, X., Sehlin, D., & Syvänen, S. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00257-0 · Cited by 80

In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain

Modarres, H. P., Janmaleki, M., Novin, M., Saliba, J., Moussa, F. E. H., Charan, M. R., Seyfoori, A., SadAbadi, H., Vandal, M., Nguyen, M. D., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.024 · Cited by 77

Mechanisms of receptor-mediated transcytosis at the blood-brain barrier

Baghirov, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113595 · Cited by 82

Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies

Yang, F., Wen, W., & Qin, W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010048 · Cited by 75

Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26

Thom, G., Burrell, M. R., Haqqani, A. S., Yogi, Á., Lessard, E., Brunette, E., Delaney, C. E., Baumann, E., Callaghan, D., Melero, N. R., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00937 · Cited by 76

Phage display derived peptides for Alzheimer's disease therapy and diagnosis

Zhang, X., Zhang, X., Gao, H., & Qing, G. (2022) · Theranostics · doi:10.7150/thno.68636 · Cited by 75

Antibody-Targeted Nanoparticles for Cancer Treatment

Carter, T. J., Mulholland, P. J., & Chester, K. A. (2016) · Immunotherapy · doi:10.2217/imt.16.11 · Cited by 71

Endothelial LRP1 – A Potential Target for the Treatment of Alzheimer’s Disease

Storck, S. E., & Pietrzik, C. U. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2267-3 · Cited by 74

Engineering antibody and protein therapeutics to cross the blood–brain barrier

Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 75

MicroRNA-Based Drugs for Brain Tumors

Anthiya, S., Griveau, A., Loussouarn, C., Baril, P., Garnett, M. C., Issartel, J., & Garcion, E. (2018) · Trends in cancer · doi:10.1016/j.trecan.2017.12.008 · Cited by 72

Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases

Bélanger, K., Iqbal, U. H., Tanha, J., MacKenzie, R., Moreno, M., & Stanimirovic, D. B. (2019) · Antibodies · doi:10.3390/antib8020027 · Cited by 71

Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs

Pornnoppadol, G., Bond, L. G., Lucas, M. J., Zupancic, J. M., Kuo, Y., Zhang, B., Greineder, C. F., & Tessier, P. M. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.09.008 · Cited by 75

Primate-conserved carbonic anhydrase IV and murine-restricted LY6C1 enable blood-brain barrier crossing by engineered viral vectors

(2023) · doi:10.1126/sciadv.adg6618 · Cited by 67

Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution

Khoury, N., Pizzo, M. E., Discenza, C. B., Joy, D. A., Tatarakis, D., Todorov, M. I., Negwer, M., Ha, C., de Melo, G. L., Sarrafha, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57108-x · Cited by 78

Active poly‐GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model

Zhou, Q., Mareljic, N., Michaelsen, M., Parhizkar, S., Heindl, S., Nuscher, B., Farny, D., Czuppa, M., Schludi, C., Graf, A., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910919 · Cited by 64

Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor

Pardridge, W. M., Boado, R. J., Patrick, D. J., Hui, E. K., & Lu, J. Z. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00730 · Cited by 62

Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier

Pardridge, W. M. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1227816 · Cited by 62

Biomarker-guided decision making in clinical drug development for neurodegenerative disorders

Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 70

In vivo imaging of alpha-synuclein with antibody-based PET

Roshanbin, S., Xiong, M., Hultqvist, G., Söderberg, L., Zachrisson, O., Meier, S. R., Ekmark‐Lewén, S., Bergström, J. J. E., Ingelsson, M., Sehlin, D., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108985 · Cited by 60

Transferrin' bispecific antibodies across the blood–brain barrier

Bray, N. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4522 · Cited by 16

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794

Novel Human/Non-Human Primate Cross-Reactive Anti-Transferrin Receptor Nanobodies for Brain Delivery of Biologics

Rué, L., Jaspers, T., Degors, I. M. S., Noppen, S., Schols, D., Strooper, B. D., & Dewilde, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061748 · Cited by 32

O1‐06‐02: Enhancing antibody uptake in brain to target BACE1

Atwal, J., Yu, J., Zhang, Y., Chen, Y., Chiu, C., Meilandt, W. J., Scearce-Levie, K. A., Lu, Y., Kenrick, M., Prabhu, S., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.234

Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants

Bien‐Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., Luk, W., Lu, Y., Dennis, M. S., Weimer, R. M., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131660 · Cited by 356